Beta-blockers have long been prescribed for secondary prevention in patients with acute myocardial infarction (MI) after clinical trials performed in the 1980′s demonstrated that their use provided significant survival benefits [1]. Although the prognosis of acute MI has improved considerably ever since due to the use and continuous refinements of reperfusion and revascularization strategies and to the advances in antithrombotic and other pharmacological therapies, current guidelines still recommend beta-blockers for all patients after a MI [2,3].
